Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across cancer, cardiovascular disease and inflammation

          Learn more

        • Cancer
        • Inflammation
        • Cardiovascular
        • Programs
        • Laboratories
        • Diseases
        • Expertises
        • Services and instrumentation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your Will
        • Donate in Memory
  • Impact
        • Impact

          Our research develops new diagnostics, treatments and cures for some of the most deadly and debilitating diseases affecting society today

          Learn more

        • Breakthroughs
        • Community and research
        • Real stories
  • Health hub
        • Health hub

          A range of practical information to assist in the possible preventions to disease through evidence-based research on how the body works.

          Learn more

        • Inflammation
        • The Good Gut Anti-Inflammatory Diet
        • Ageing
        • Exercise snack program
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
        • Careers and studies
        • Contact
  • Donate
    Centenary Institute > Alcoholic Liver Disease Program

Alcoholic Liver Disease Program

The Alcoholic Liver Disease research program includes studies on genetics of alcoholic cirrhosis and molecular mechanisms underlying liver disease. By identifying biomarkers for alcohol use and liver injury, we utilise transcriptomics, lipid and miRNA profiling to find treatment targets and pathways.

Alcoholic liver disease has the highest mortality amongst all alcohol related disorders and needs further research. There is no effective treatment for this debilitating hidden epidemic. The overall goal of this research is to understand the mechanisms of how alcohol injures the liver and identify potential genetic/non-genetic bio-markers for therapy and diagnosis. Dr Seth’s research program addresses the following clinical and fundamental issues for better understanding of this disease leading to improved patient care.

Why do only some drinkers get cirrhosis while others who drink similar levels do not? To answer one of the big questions in this field Dr Seth leads a NIH/NIAAA (USA) funded multinational GenomALC Consortium. The focus of the consortium is to explore genome wide genetic and epigenetic factors that predispose some drinkers to and protect others from developing ALD. This program has created one of the largest biobank and clinical database of thousands of heavy chronic drinkers with great potential for future studies.

Establishing blood biomarkers of alcohol consumption and alcoholic liver disease. Current markers for alcohol consumption and self-report are sub-optimal and unreliable. Seth and her team have established tests using UHPLC-MS/MS (Clinical Pathology, RPAH) for measuring direct metabolites of alcohol (PEth, EtG and EtS) as serum biomarkers for alcohol consumption. Development of and access to these tests will significantly improve the screening and monitoring of alcohol use in individuals with alcohol-related problems, such as addiction, pre- and post-liver transplant, alcohol dependence treatment and in other non-clinical settings (social services, workplace, prison, driving, judicial, forensics, court disputes).

Understanding the cellular/molecular mechanisms of alcohol-induced liver injury and liver regeneration. (i) Seth laboratory has established in vitro and in vivo models of alcohol and alcohol plus high fat diet to study mechanisms of liver injury. In particular, role of Osteopontin (first reported in ALD by Seth) in fibrogenesis. (ii) The group has identified rare circulating endothelial progenitor cells (EPCs) altered with alcohol in human and mice that may have a role in angiogenesis mediated liver regeneration during injury. (iii) Another large international project is to identify microRNAs (miRNAs) as novel diagnostic markers in liver and kidney toxicity due to prescription drugs (e.g. paracetamol) and poisoning (e.g. pesticides, snakebite).

Clinical Professor Devanshi Seth

Head, Alcoholic Liver Disease Program

Australian

Edith Collins Centre Drug Health Services, Sydney Local Health District
QIMR Berghofer Medical Research Institute
Royal Prince Alfred Hospital
University of Newcastle
University of Sydney

 

International

Assistance Publique Hopitaux Paris (APHP), France
Center for Liver Diseases, University of Pittsburgh Medical Center, USA
CHU de Montpellier, France
CHU de Nimes, France
CHU Lille, France
CHU Rennes, France
Clinique d’Hépatologie Brussels, Belgium
Department of Medical and Molecular Genetics, Indiana University, USA
Department of Metabolism, Digestion and Reproduction, Imperial College London, UK
Hôpital Antoine-Béclère, France
Hopital Universitaire Antoine Beclere (APHP), France
Hôpital Universitaire Caremeau, France
Hopital Universitaire Jean Verdier (APHP), France
Hopital Universitaire Pitie Salpetriere (APHP), France
Indiana University, USA
Institut National de la Sante Et de la Recherche Medicale (Inserm), France
Institute for Liver & Digestive Health, Imperial College, UK
Institute of Liver Biliary Sciences (ILBS), India
L’hôpital Universitaire Carémeau, France
Lerner Research Institute, USA
Molecular Psychiatry Laboratory, University College London, UK
MRC Centre for Drug Safety Science and Liverpool Centre for Alcohol Research, University of Liverpool, UK
Newcastle Freeman Hospital, UK
Newcastle University, UK
Newcastle Upon Tyne Hospital, UK
NIH National Institute on Alcohol Abuse Alcoholism (NIAAA), USA
Nottingham University Hospital, UK
Privatklin Meiringen, Switzerland
Psychiatry Hospital University Munich, Germany
Purdue University, USA
Salem Medical Center, USA
Service Addictologie CHRU Carémeau, France
Sorbonne Universite, France
Technical University of Munich, Germany
Translational Genomics Group, Inflammatory Bowel & Immunobiology Research Institute, USA
UCL Institute for Liver & Digestive Health, Division of Medicine, University College London, UK
Universite de Montpellier, France
Universite de Rennes 1, France
Université Libre de Bruxelles, Belgium
University Hospital Zurich, Switzerland
University of California, USA
University of Liverpool, UK
University of North Carolina, USA
University of Nottingham, UK
University of Sheffield, UK
University of Zurich, Switzerland
US Department of Veterans Affairs, USA
VA Long Beach Healthcare System, USA

Themes

  • Inflammation

    Inflammation

Head

  • Clinical Professor Devanshi Seth

    Head, Alcoholic Liver Disease Program

    Phone number Phone Number 02 9565 6268

    Email Email d.seth@sydney.edu.au

Research Fields

  • Liver disease

Topics

  • Chronic diseases ,

Expertise

  • Epigenetics ,

Publications

Recent publications

Search amongst our repository

all publications

For access to all Publications via Pub Med.

Why do only some drinkers get cirrhosis while others who drink similar levels do not? To answer one of the big questions in this field Dr Seth leads a NIH/NIAAA (USA) funded multinational GenomALC Consortium. The focus of the consortium is to explore genome wide genetic and epigenetic factors that predispose some drinkers to and protect others from developing ALD. This program has created one of the largest biobank and clinical database of thousands of heavy chronic drinkers with great potential for future studies.

Establishing blood biomarkers of alcohol consumption and alcoholic liver disease. Current markers for alcohol consumption and self-report are sub-optimal and unreliable. Seth and her team have established tests using UHPLC-MS/MS (Clinical Pathology, RPAH) for measuring direct metabolites of alcohol (PEth, EtG and EtS) as serum biomarkers for alcohol consumption. Development of and access to these tests will significantly improve the screening and monitoring of alcohol use in individuals with alcohol-related problems, such as addiction, pre- and post-liver transplant, alcohol dependence treatment and in other non-clinical settings (social services, workplace, prison, driving, judicial, forensics, court disputes).

Understanding the cellular/molecular mechanisms of alcohol-induced liver injury and liver regeneration. (i) Seth laboratory has established in vitro and in vivo models of alcohol and alcohol plus high fat diet to study mechanisms of liver injury. In particular, role of Osteopontin (first reported in ALD by Seth) in fibrogenesis. (ii) The group has identified rare circulating endothelial progenitor cells (EPCs) altered with alcohol in human and mice that may have a role in angiogenesis mediated liver regeneration during injury. (iii) Another large international project is to identify microRNAs (miRNAs) as novel diagnostic markers in liver and kidney toxicity due to prescription drugs (e.g. paracetamol) and poisoning (e.g. pesticides, snakebite).

Clinical Professor Devanshi Seth

Head, Alcoholic Liver Disease Program

Australian

Edith Collins Centre Drug Health Services, Sydney Local Health District
QIMR Berghofer Medical Research Institute
Royal Prince Alfred Hospital
University of Newcastle
University of Sydney

 

International

Assistance Publique Hopitaux Paris (APHP), France
Center for Liver Diseases, University of Pittsburgh Medical Center, USA
CHU de Montpellier, France
CHU de Nimes, France
CHU Lille, France
CHU Rennes, France
Clinique d’Hépatologie Brussels, Belgium
Department of Medical and Molecular Genetics, Indiana University, USA
Department of Metabolism, Digestion and Reproduction, Imperial College London, UK
Hôpital Antoine-Béclère, France
Hopital Universitaire Antoine Beclere (APHP), France
Hôpital Universitaire Caremeau, France
Hopital Universitaire Jean Verdier (APHP), France
Hopital Universitaire Pitie Salpetriere (APHP), France
Indiana University, USA
Institut National de la Sante Et de la Recherche Medicale (Inserm), France
Institute for Liver & Digestive Health, Imperial College, UK
Institute of Liver Biliary Sciences (ILBS), India
L’hôpital Universitaire Carémeau, France
Lerner Research Institute, USA
Molecular Psychiatry Laboratory, University College London, UK
MRC Centre for Drug Safety Science and Liverpool Centre for Alcohol Research, University of Liverpool, UK
Newcastle Freeman Hospital, UK
Newcastle University, UK
Newcastle Upon Tyne Hospital, UK
NIH National Institute on Alcohol Abuse Alcoholism (NIAAA), USA
Nottingham University Hospital, UK
Privatklin Meiringen, Switzerland
Psychiatry Hospital University Munich, Germany
Purdue University, USA
Salem Medical Center, USA
Service Addictologie CHRU Carémeau, France
Sorbonne Universite, France
Technical University of Munich, Germany
Translational Genomics Group, Inflammatory Bowel & Immunobiology Research Institute, USA
UCL Institute for Liver & Digestive Health, Division of Medicine, University College London, UK
Universite de Montpellier, France
Universite de Rennes 1, France
Université Libre de Bruxelles, Belgium
University Hospital Zurich, Switzerland
University of California, USA
University of Liverpool, UK
University of North Carolina, USA
University of Nottingham, UK
University of Sheffield, UK
University of Zurich, Switzerland
US Department of Veterans Affairs, USA
VA Long Beach Healthcare System, USA

News

  • What happens to people who consume hazardous amounts of alcohol?

    Clinical Professor Devanshi Seth, Head of the Centenary Institute’s Alcoholic Liver Disease Laboratory is co-author on a newly published study that has identified factors affecting mortality in people drinking extreme amounts of alcohol.
    Date 14 Nov 2022
  • Genetic risk test developed to predict alcohol-related cirrhosis of the liver

    An international research group led by the Centenary Institute has developed a world first genetic risk score (GRS) test able to identify patients at high-risk of developing alcohol-related cirrhosis.
    Date 24 Oct 2021
  • Reducing cirrhosis threat for high-risk drinkers

    Research led by the Centenary Institute has shown that a healthy weight and coffee consumption may help lower the risk of high-risk drinkers developing alcohol-induced cirrhosis (scarring of the liver), which causes approximately 300,000 deaths globally each year.
    Date 02 Sep 2020
View all

Twitter

Tweets by SethDevanshi Follow us (links open in a new window)

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Programs
  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram